跳转到主要内容
MRG — Bridge to Success

Pharmaceuticals

药品阿联酋

阿联酋药品定价监管——战略与法规考量

在阿联酋,药品定价并非纯商业决策,而是注册流程中的受监管环节,需要战略规划并符合法规要求。

MRG Regulatory TeamApr 20263 min read00 次阅读
MRGEDE

本文目前仅提供英文版本,完整翻译正在准备中。

In the UAE, pharmaceutical pricing is not purely commercial – it is a regulated component of the registration process. Pricing approval is integrated within MOHAP’s evaluation framework and must align with official pricing policies. Failure to prepare an accurate pricing submission can delay approval even if the technical dossier is complete.

01

Pricing as a Regulatory Step

Pricing review typically occurs during or after technical evaluation. Approval of the product does not automatically guarantee pricing approval.

Country of origin price certificate Public price documentation Proposed CIF price Justification for price positioning

02

Reference Pricing Considerations

Reference country prices Regional GCC pricing comparisons Therapeutic category benchmarking Generic vs. originator pricing structures Incorrect or unsupported price declarations may result in revision requests.

03

CIF & Margin Structure

Understanding cost structure is essential:

CIF (Cost, Insurance, Freight) Importer margin Distributor margin Pharmacy margin Transparent financial documentation strengthens approval probability.

04

Strategic Recommendations

Align regional pricing strategy before submission Ensure documentation consistency Avoid price discrepancies between markets

相关 MRG 服务

对本指南有疑问?

请发送给我们,我们的法规顾问将在24小时内回复。

本网站受 reCAPTCHA 保护,适用 Google 隐私政策和服务条款。